Piramal to expand in API manufacturing capabilities with $55m


Piramal Pharma Solutions (PPS) is set to invest $55m across its production sites in North America and Asia in order to expand its active pharmaceutical ingredients (API) manufacturing capabilities and capacities.

PPS, a subsidiary of Piramal Enterprises (PEL), is a major contract development and manufacturing organisation (CDMO).

The company will use a part of its investment for the development of its new and advanced multi-purpose plants with more than 270kl total capacity.

The facilities will help support PPS’s current pipeline of nearly 80 late-stage programmes designed by the company to assist its partners at several sites worldwide.

The investment will also be used to expand the firm’s potency footprint at its production plant in Riverview, Michigan, US.

"With these investments, we can now support the commercialisation of our pipeline of over 80 programmes that are at Phase II or beyond, while allowing us additional capacity for future partnerships."

PPS CEO Vivek Sharma said: “We are committed towards investing in our customers' future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programmes that are at Phase II or beyond, while allowing us additional capacity for future partnerships.”

In addition, PPS aims to increase its early development capabilities out of Ennore, India, through the development of good manufacturing practices (GMP) kilo labs and a pilot plant.

The company will add early development capabilities in both drug substance and drug product out of its Morpeth, UK, facility in order to provide better service to its European biotech customers.

Support functions such as analytical capabilities, research and development infrastructure, automation, and IT systems will also be expanded by the company.

Piramal supports API development and production through an integrated model across its five manufacturing sites in North America, Europe and Asia.